Serial Number
98426370
Owner
Immix Biopharma, Inc.Attorney
Sheila R. GibsonFiling Date
Feb 28, 2024
SMARXT Trademark
Serial Number: 98426370
Trademark Classes
Owner Contact Info
Legal Representation
Correspondence Address
Sheila R. Gibson Aura IP Law
3217 Carson Street #294
Lakewood, CA 90712
United States
Trademark Details
Filing Date
February 28, 2024
Registration Date
Not Registered
Published for Opposition
October 22, 2024
Goods & Services
anti-cancer preparations; anti-cancer drugs; compounds for treating cancer; pharmaceuticals for the treatment of cancer; pharmaceutical products for the treatment of cancer; pharmaceutical preparations and substances for the treatment of cancer; pharmaceutical compositions for the treatment of cancer; pharmaceutical drugs for the treatment of cancer; pharmaceutical preparations for human use for the treatment of cancer; pharmaceutical preparations and substances for the treatment of treatment-resistant cancers biological preparations for the treatment of cancer; biological preparations for medical purposes for the treatment of cancer; medical preparations for the treatment of cancer; medicinal preparations and substances for the treatment of cancer; medicines for human purposes for the treatment of cancer; injectable pharmaceuticals for the treatment of cancer; compounds for treating resistant cancers; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations for use in chemotherapy; anti-tumor preparations; anti-tumor drugs; tumor suppressing agents; pharmaceutical preparations for suppressing tumors; preparations for treating malignant tumors; medicines for the treatment of gastrointestinal diseases; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; pharmaceutical preparations for treating gastrointestinal disorders
scientific research in the field of oncology; scientific research in the field of immuo-dysregulated diseases; development of pharmaceutical preparations and medicines for the treatment of cancer; development of pharmaceutical preparations and medicines for the treatment of immuno-dysregulated diseases; clinical research in the field of oncology; clinical research in the field of immuo-dysregulated diseases; research and development services in the field of anti-cancer preparations; research and development services in the field of preparations for treating immuno-dysregulated diseases; design, engineering, research, development and testing services in the field of oncology; design, engineering, research, development and testing services in the field of immuno-dysregulated diseases; providing information regarding medical research relating to oncology; providing information regarding medical research relating to immuno-dysregulated diseases